Free Trial

Assertio (NASDAQ:ASRT) Stock Price Down 3.7% - Here's What Happened

Assertio logo with Medical background

Assertio Holdings, Inc. (NASDAQ:ASRT - Get Free Report)'s share price dropped 3.7% during mid-day trading on Tuesday . The stock traded as low as $0.66 and last traded at $0.66. Approximately 151,355 shares changed hands during mid-day trading, a decline of 71% from the average daily volume of 529,629 shares. The stock had previously closed at $0.69.

Analysts Set New Price Targets

ASRT has been the topic of several recent research reports. HC Wainwright reiterated a "buy" rating and issued a $3.50 price target on shares of Assertio in a report on Monday, May 19th. Alliance Global Partners restated a "buy" rating on shares of Assertio in a report on Tuesday, May 13th. Finally, Wall Street Zen cut Assertio from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd.

Check Out Our Latest Stock Report on ASRT

Assertio Price Performance

The company has a current ratio of 1.66, a quick ratio of 1.35 and a debt-to-equity ratio of 0.36. The firm has a market cap of $65.32 million, a P/E ratio of -2.12 and a beta of 0.29. The company has a fifty day moving average price of $0.66 and a two-hundred day moving average price of $0.71.

Assertio (NASDAQ:ASRT - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.08). Assertio had a negative net margin of 25.72% and a negative return on equity of 24.87%. The firm had revenue of $26.49 million during the quarter, compared to analyst estimates of $27.52 million. During the same period in the prior year, the business posted $0.04 EPS. Equities analysts anticipate that Assertio Holdings, Inc. will post -0.15 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ASRT. Marshall Wace LLP bought a new position in shares of Assertio during the 4th quarter worth approximately $64,000. Stifel Financial Corp acquired a new position in shares of Assertio during the 4th quarter worth $27,000. Commonwealth Equity Services LLC acquired a new position in shares of Assertio during the 4th quarter worth $30,000. Northern Trust Corp increased its holdings in Assertio by 21.3% in the 4th quarter. Northern Trust Corp now owns 227,217 shares of the company's stock worth $198,000 after purchasing an additional 39,906 shares in the last quarter. Finally, Two Sigma Investments LP increased its holdings in Assertio by 3.9% in the 4th quarter. Two Sigma Investments LP now owns 910,046 shares of the company's stock worth $793,000 after purchasing an additional 34,004 shares in the last quarter. Institutional investors and hedge funds own 48.96% of the company's stock.

About Assertio

(Get Free Report)

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.

Further Reading

Should You Invest $1,000 in Assertio Right Now?

Before you consider Assertio, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Assertio wasn't on the list.

While Assertio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
This Strategy Beat the S&P—And Most Investors Ignore It
NVDA Greenlight: China Sales Spark 50% Rally Potential

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines